Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMedical Mutual - Ohio Addyi Prior Auth Coverage | …
    Ask Trek AI about this page
    Currentmedical mutual - ohioPolicy N/A

    Recommended Authorization Criteria — Addyi (flibanserin)

    Customize your policy alerts

    Sign up for all medical mutual - ohio policy alerts

    Know when medical mutual - ohio releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Recommended prior authorization criteria for pharmacy coverage of Addyi (flibanserin) for treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)/female sexual interest/arousal disorder (FSIAD). Applies to prescribers requesting coverage through Medical Mutual - Ohio.

    Policy Summary
    Payermedical mutual - ohio
    PolicyAddyi (flibanserin) prior authorization
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateJan 15, 2026
    Last ReviewJan 15, 2026
    Next Review DateJan 15, 2026
    Key ActionObtain prior authorization and document that the patient is a premenopausal woman with acquired generalized HSDD/FSIAD and meets all coverage criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100 mg/daymax dose
    60 daysinitial approval
    180 daysextended approval
    pre-menopausal <65population

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Addyi (flibanserin)

    inv-01: Initial Therapy

    Covered when ALL of the following are met

    Initial Therapy - Acquired, Generalized HSDD/FSIAD: A. The patient is an adult woman younger than 65 years of age; AND B. The patient has a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD)/female sexual interest/arousal disorder (FSIAD) consistent with the current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM); AND C. The patient has had normal sexual desire in the past, prior to the diagnosis of HSDD/FSIAD; AND D. The patient's low sexual desire is NOT caused by: a co-existing medical or psychiatric condition; problems within the relationship; the effects of medication or other drug substances (e.g., antidepressants); or drug abuse; AND E. The prescriber has counseled the patient regarding the interaction of Addyi with alcohol and the increased risk of hypotension and syncope; AND F. Patient does not have hepatic impairment; AND G. Patient will not use Addyi concurrently with CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin); AND H. Patient will not exceed the maximum recommended dose of 100 mg taken once daily at bedtime; AND I. Patient is not currently pregnant or breastfeeding

    inv-02: Continuation of Therapy

    Covered for continuation when ALL of the following are met

    Continuation Therapy: A. The patient continues to meet all criteria for new starts (see Initial Therapy); AND B. Patient has been evaluated and has seen improvement on Addyi defined by an increase in satisfying sexual events, and/or improvement in sexual desire, as determined by the prescriber; AND C. The patient has not reported any serious or concerning adverse events (e.g., hypotension, syncope, dizziness) while using Addyi

    Use of Addyi (flibanserin) is not recommended for the following situations: treatment of HSDD/FSIAD in men; use solely to enhance sexual performance; and any indications or circumstances that are not listed in the Recommended Authorization Criteria.

    Clinical evidence for Addyi is limited or not supportive for certain populations. Data do not support routine use in men, and evidence for postmenopausal women is limited; accordingly, Addyi is not recommended for enhancement-of-performance indications or other uses outside the stated authorization criteria.

    Initial Therapy — Authorization Conditions

    inv-11: Initial Therapy

    Initial approval is recommended when criteria are met.

    Initial Therapy: See Initial Therapy criteria: premenopausal adult women younger than 65 with acquired, generalized HSDD/FSIAD consistent with DSM; prior normal sexual desire; low desire not secondary to medical/psychiatric conditions, relationship problems, medication/substance effects, or drug abuse; prescriber counseling on alcohol interaction and increased risk of hypotension and syncope; no hepatic impairment; no concurrent CYP3A4 inhibitor use (e.g., ketoconazole, clarithromycin); maximum recommended dose 100 mg once daily at bedtime; not pregnant or breastfeeding.

    Initial approval duration 60 days

    Continuation Therapy — Renewal Conditions

    inv-12: Continuation Therapy

    Continuation approval requires ongoing benefit and absence of serious adverse events.

    Continuation: Patient continues to meet initial criteria; demonstrated improvement per prescriber (increase in satisfying sexual events and/or improvement in sexual desire); no serious or concerning adverse events (e.g., hypotension, syncope, dizziness) while using Addyi.

    Extended approval duration 180 days may be considered per policy guidance

    Provider Requirements and Administrative Notes

    Prior Authorization

    Prior authorization required when coverage criteria met

    Prior authorization is recommended for pharmacy benefit coverage of Addyi; approval is recommended when the patient meets the specified criteria for diagnosis and other clinical conditions (see Coverage Criteria and Initial/Continuation Therapy requirements). Initial approvals are provided for the initial approval duration and reauthorization requires a response to therapy unless otherwise noted.

    Step Therapy

    No step therapy requirements

    No step therapy requirements are specified in this policy.

    Documentation Required

    Key Definitions

    HSDD/FSIAD — definition
    DefinitionAcquired, generalized hypoactive sexual desire disorder (HSDD)/female sexual interest/arousal disorder (FSIAD) characterized by low sexual desire that causes marked distress or interpersonal difficulty
    Not secondary to other causesThe low sexual desire is NOT due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance
    PopulationApplies to premenopausal women (indication for Addyi)
    Clinical relevanceDiagnosis requires that symptoms cause marked distress or interpersonal difficulty
    TerminologyHSDD and FSIAD are used to describe acquired, generalized low sexual desire/interest/arousal

    Background

    Addyi (flibanserin) is indicated for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD)/female sexual interest/arousal disorder (FSIAD) in premenopausal women. The policy restricts authorization to this population and requires that the low sexual desire be causing marked distress or interpersonal difficulty and not be secondary to medical/psychiatric conditions, relationship problems, or effects of medications or substances. Safety considerations noted in the policy include the risk of hypotension and syncope with alcohol and contraindications such as hepatic impairment and concurrent use of CYP3A4 inhibitors.

    Policy Summary
    Payermedical mutual - ohio
    PolicyAddyi (flibanserin) prior authorization
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateJan 15, 2026
    Last ReviewJan 15, 2026
    Next Review DateJan 15, 2026
    Key ActionObtain prior authorization and document that the patient is a premenopausal woman with acquired generalized HSDD/FSIAD and meets all coverage criteria.
    SourceLink
    On This Page
    Coverage Criteria for Addyi (flibanserin)Initial Therapy — Authorization ConditionsContinuation Therapy — Renewal ConditionsProvider Requirements and Administrative NotesKey DefinitionsBackground

    Provide documentation on request to support medical necessity

    The Company may request additional documentation to support medical necessity as part of its coverage determination; requested documentation must be made available upon request.

    • Documentation may include patient records, test results, and provider credentials.
    • Provide requested materials promptly to support the coverage determination.
    Denial Risk

    Denial risk for non‑medical necessity, investigational use, or out‑of‑scope services

    The Company may deny reimbursement if the drug or services are not medically necessary, are investigational/experimental, are not within the member's benefit scope, or if inappropriate/excessive billing is found.

    • Denial may occur for uses not listed in the policy unless medical necessity and efficacy are shown on review.
    • A pattern of inappropriate or excessive billing may also result in denial.